Royalty Pharma plc – NASDAQ:RPRX
Founder-led company
Royalty Pharma stock price today
$35.74
+10.20
+39.94%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
Royalty Pharma stock price monthly change
-4.59%
month
Royalty Pharma stock price quarterly change
-4.59%
quarter
Royalty Pharma stock price yearly change
-8.82%
year
Royalty Pharma key metrics
Market Cap | 11.10B |
Enterprise value | 18.00B |
P/E | 9.98 |
EV/Sales | 7.94 |
EV/EBITDA | 8.38 |
Price/Sales | 5.00 |
Price/Book | 1.66 |
PEG ratio | 0.24 |
EPS | 1.79 |
Revenue | 2.23B |
EBITDA | 981.98M |
Income | 798.85M |
Revenue Q/Q | -16.95% |
Revenue Y/Y | -5.11% |
Profit margin | 50.54% |
Oper. margin | 68.14% |
Gross margin | 70.53% |
EBIT margin | 68.14% |
EBITDA margin | 43.87% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRoyalty Pharma stock price history
Royalty Pharma stock forecast
Royalty Pharma financial statements
| Jun 2023 | 538.20M | 227.62M | 42.29% |
|---|---|---|---|
| Sep 2023 | 536.31M | 72.11M | 13.45% |
| Dec 2023 | 596M | 494.34M | 82.94% |
| Mar 2024 | 567.97M | 4.77M | 0.84% |
| Mar 2024 | 567.97M | 4.77M | 0.84% |
|---|---|---|---|
| Sep 2025 | 783M | 518.01M | 66.16% |
| Oct 2025 | 793M | 693.07M | 87.4% |
| Dec 2025 | 840M | 800.62M | 95.31% |
Analysts Price target
Financials & Ratios estimates
3.28%
Yield TTM
| Payout ratio | 32.5% |
|---|
| 2019 | 4.54% |
|---|---|
| 2020 | 2.12% |
| 2021 | 1.73% |
| 2022 | 1.93% |
| 2023 | 2.85% |
| Jun 2023 | 17121482000 | 7.30B | 42.68% |
|---|---|---|---|
| Sep 2023 | 15855524000 | 6.27B | 39.55% |
| Dec 2023 | 16381851000 | 6.29B | 38.44% |
| Mar 2024 | 16130886000 | 6.26B | 38.85% |
| Jun 2023 | 607.81M | -63.43M | -346.99M |
|---|---|---|---|
| Sep 2023 | 573.52M | -450.65M | -1.35B |
| Dec 2023 | 777.28M | -998.75M | -237.97M |
| Mar 2024 | 669.60M | -90.18M | -213.42M |
Royalty Pharma alternative data
| Feb 2024 | 75 |
|---|---|
| Mar 2024 | 75 |
| Apr 2024 | 75 |
| May 2024 | 75 |
| Jun 2024 | 75 |
| Jul 2024 | 75 |
Royalty Pharma other data
64.22%
+20.16%
of RPRX is owned by hedge funds
263
+8
266.36M
-1.15M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2023 | 0 | 48333 |
| Mar 2023 | 0 | 252729 |
| May 2023 | 380000 | 1750000 |
| Jun 2023 | 220000 | 192221 |
| Jul 2023 | 0 | 75000 |
| Aug 2023 | 0 | 75000 |
| Dec 2023 | 0 | 1000000 |
| Jan 2024 | 0 | 470000 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Royalty Pharma: Key Strategic Updates To Be Priced In
PeptiDream: Opulent Dream Now A Reality
Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Cytokinetics, Incorporated: Buyout Speculation Persists
Royalty Pharma: One Of The Best Names In Pharmaceuticals
Innoviva: A Lot Of Moving Parts
Royalty Pharma: The Time Has Come
Biopharma Bounce-Back: From Policy Pains To Profitable Plains
Royalty Pharma: We Continue To Like The Strategy And Sell-Off Is Overdone
-
What's the price of Royalty Pharma stock today?
One share of Royalty Pharma stock can currently be purchased for approximately $35.74.
-
When is Royalty Pharma's next earnings date?
Unfortunately, Royalty Pharma's (RPRX) next earnings date is currently unknown.
-
Does Royalty Pharma pay dividends?
Yes, Royalty Pharma pays dividends and its trailing 12-month yield is 3.29% with 32% payout ratio. The last Royalty Pharma stock dividend of $0.19 was paid on 15 Mar 2022.
-
How much money does Royalty Pharma make?
Royalty Pharma has a market capitalization of 11.10B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 5.24% to 2.35B US dollars.
-
What is Royalty Pharma's stock symbol?
Royalty Pharma plc is traded on the NASDAQ under the ticker symbol "RPRX".
-
What is Royalty Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Royalty Pharma?
Shares of Royalty Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Royalty Pharma's key executives?
Royalty Pharma's management team includes the following people:
- Mr. Pablo Gerardo Legorreta Founder, Chairman & Chief Executive Officer(age: 61, pay: $55,670,000)
- Mr. Christopher Hite Vice Chairman & Executive Vice President(age: 57, pay: $3,800,000)
- Mr. George Wingate Lloyd Executive Vice President of Investments & Gen. Counsel(age: 66, pay: $3,400,000)
- Dr. James Folmar Reddoch Ph.D. Executive Vice President, Chief Scientific Officer and Co-Head of Research & Investments(age: 55, pay: $3,400,000)
-
Is Royalty Pharma founder-led company?
Yes, Royalty Pharma is a company led by its founder Mr. Pablo Gerardo Legorreta.
-
How many employees does Royalty Pharma have?
As Jul 2024, Royalty Pharma employs 75 workers.
-
When Royalty Pharma went public?
Royalty Pharma plc is publicly traded company for more then 5 years since IPO on 16 Jun 2020.
-
What is Royalty Pharma's official website?
The official website for Royalty Pharma is royaltypharma.com.
-
Where are Royalty Pharma's headquarters?
Royalty Pharma is headquartered at 110 East 59th Street, New York, NY.
-
How can i contact Royalty Pharma?
Royalty Pharma's mailing address is 110 East 59th Street, New York, NY and company can be reached via phone at +212 8830200.
Royalty Pharma company profile:
Royalty Pharma plc
royaltypharma.comExchange:
NASDAQ
Full time employees:
75
Industry:
Biotechnology
Sector:
Healthcare
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
110 East 59th Street
New York, NY 10022
New York, NY 10022
CIK: 0001802768
ISIN: GB00BMVP7Y09
CUSIP: G7709Q104
